Our Objectives
The Cancer Therapeutics Research Group (CTRG) was formed in October 1997 by Professor John Wong (National University Health System) and Professor James Bishop (Sydney Cancer Centre and University of Sydney) to develop new therapeutic strategies for cancers common to Asia-Pacific.
This resulted in a joint research group which performs clinical trials on new anti-cancer drugs in Asia-Pacific, and aims to be the equivalent of oncology cooperative groups in the USA.
The CTRG has rapidly established itself and is now recognised as the leading group for evaluating new therapeutic strategies in the Asia-Pacific region.
Translational Research
The need for high quality and well coordinated clinical trial groups in Asia-Pacific has provided many opportunities for the CTRG in clinical trials and translational research, having-established itself as a leader in this region.
The institutions forming the CTRG collectively bring extensive experience in oncology drug development.
Investigators from the various CTRG institutions actively discuss and design in-house research studies. We are recognised by the United States National Cancer Institute (NCI) through the formation of an agreement for the conduct of clinical trials, which allows the NCI and CTRG to collaborate and test promising new drugs in Asian cancers at a level which will allow the studies to support United States Food and Drug Administration (FDA) registration of the new drugs.
Organisation Structure
The administrative head office is located in the National University Hospital, Singapore. Our group is led by a Joint Management Committee (JMC), comprising of the Directors of each member institution and a Chairman elected on an annual rotating basis.
